NCT05556395 Global Blood-Brain Barrier Disruption and Post-Stroke Cognitive Decline
| NCT ID | NCT05556395 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Johns Hopkins University |
| Condition | Ischemic Stroke |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2022-04-01 |
| Primary Completion | 2027-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2022-04-01 with a primary completion date of 2027-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to gain a better understanding of why some individuals who have suffered a stroke experience post-stroke cognitive decline. Specifically this study is testing whether global disruption of the blood-brain barrier detected at the time of the stroke is informative about the risk of post-stroke cognitive decline over the next 3 years.
Eligibility Criteria
Inclusion Criteria: * Acute ischemic stroke demonstrated on an MRI scan that includes perfusion imaging with an exogenous contrast agent Exclusion Criteria: * Inability to perform telephone-based cognitive assessments
Contact & Investigator
Richard Leigh, MD
PRINCIPAL INVESTIGATOR
Johns Hopkins University
Frequently Asked Questions
Who can join the NCT05556395 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Ischemic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05556395 currently recruiting?
Yes, NCT05556395 is actively recruiting participants. Contact the research team at dechava1@jhu.edu for enrollment information.
Where is the NCT05556395 trial being conducted?
This trial is being conducted at Baltimore, United States.
Who is sponsoring the NCT05556395 clinical trial?
NCT05556395 is sponsored by Johns Hopkins University. The principal investigator is Richard Leigh, MD at Johns Hopkins University. The trial plans to enroll 150 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.